Servier Acquires Day One Biopharmaceuticals

Servier, an independent international pharmaceutical group, has completed the tender offer to acquire all the issued and outstanding shares of common stock of Day One Biopharmaceuticals Inc., a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, for $21.50 per share.

The acquisition strengthens Servier’s leadership in low-grade glioma and expands the group’s position in oncology with the addition of a marketed product and pipeline focused on rare cancers.

Day One’s portfolio includes OJEMDATM (tovorafenib), an FDA-approved medicine in pediatric low-grade glioma, the most common form of childhood brain tumor, Emi-Le (emiltatug ledadotin), a novel antibody drug conjugate (ADC), and DAY301, a targeted therapy in rare cancers.

“Welcoming Day One to Servier marks an important next chapter in how we are expanding our presence in oncology in the U.S. and strengthening our ability to deliver for patients,” said David K. Lee, Executive Vice President, USA, and CEO, Servier Pharmaceuticals. “Day One is joining us with strong science, an approved medicine, and a team that knows how to turn innovation into real outcomes for patients. This is about combining focus with execution to deliver for patients with rare cancers.”

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.